Literature DB >> 22036716

Patient acceptance and attitude toward an alternative method of subconjunctival injection for the medical treatment of glaucoma.

Rachel S Chong1, Daniel H W Su, Andrew Tsai, Yuzhen Jiang, Hla Myint Htoon, Ecosse L Lamoureux, Tin Aung, Tina T Wong.   

Abstract

PURPOSE: Nonadherence to glaucoma medications may be a major cause of treatment failure. We examined the acceptance of glaucoma patients toward a possible new route of administering glaucoma medication by subconjunctival injection. PATIENTS AND METHODS: Patients were recruited from specialist glaucoma clinics on a voluntary basis. Trained interviewers administered a 30-item questionnaire and an information sheet with details of an alternative subconjunctival injection route involving injections at 3-month intervals. Outcome measures regarding acceptance of the new procedure, social situational factors, disease factors, and treatment factors were assessed.
RESULTS: A total of 151 patients participated in this study. Of the 151 patients 112 (74.2%) were willing to have their glaucoma medication given by the new method of subconjunctival injection, 101 of 112 (90.2%) were willing to accept it at the same cost as their present medication, and 87 of 101 (86.1%) were willing to accept it even at a higher cost. These patients tended to be on a greater number of medications (P=0.006), and medicating more frequently in a day (P=0.003). Nine of 10 (90%) patients who were admitted to nonadherence were willing to accept subconjunctival injections at 3-month intervals in place of their topical medication.
CONCLUSIONS: Our study found that 74% of glaucoma patients were willing to accept an alternative form of glaucoma treatment through 3-monthly subconjunctival injections. A large proportion of patients who were admitted to nonadherence to topical medication were willing to consider this alternative method of medication. Our findings are helpful when developing patient-acceptable drug-delivery regimes, which may alleviate the need for daily medication.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22036716     DOI: 10.1097/IJG.0b013e318237c6c4

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  7 in total

1.  Nanomedicine for glaucoma: sustained release latanoprost offers a new therapeutic option with substantial benefits over eyedrops.

Authors:  Tina T Wong; Gary D Novack; Jayaganesh V Natarajan; Ching Lin Ho; Hla M Htoon; Subbu S Venkatraman
Journal:  Drug Deliv Transl Res       Date:  2014-08       Impact factor: 4.617

2.  Polyester-based microdisc systems for sustained release of neuroprotective phosphine-borane complexes.

Authors:  David A Janus; Christopher J Lieven; Megan E Crowe; Leonard A Levin
Journal:  Pharm Dev Technol       Date:  2017-06-09       Impact factor: 3.133

3.  Nanosponge-Mediated Drug Delivery Lowers Intraocular Pressure.

Authors:  Wendi S Lambert; Brian J Carlson; Alice E van der Ende; Grace Shih; Julia N Dobish; David J Calkins; Eva Harth
Journal:  Transl Vis Sci Technol       Date:  2015-01-13       Impact factor: 3.283

4.  Public Knowledge, Attitude, and Perception Toward Conventional and Novel Ocular Treatment in Malaysia.

Authors:  Siti Nabilah Abdullah; Awis Sukarni Mohmad Sabere
Journal:  J Pharm Bioallied Sci       Date:  2020-12-21

Review 5.  A Review of the Emerging Role of Silk for the Treatment of the Eye.

Authors:  Simon H Tran; Clive G Wilson; F Philipp Seib
Journal:  Pharm Res       Date:  2018-11-05       Impact factor: 4.200

6.  28-day intraocular pressure reduction with a single dose of brimonidine tartrate-loaded microspheres.

Authors:  Morgan V Fedorchak; Ian P Conner; Carlos A Medina; Jeremy B Wingard; Joel S Schuman; Steven R Little
Journal:  Exp Eye Res       Date:  2014-06-28       Impact factor: 3.467

7.  Genome-wide transcriptional analysis of differentially expressed genes in diabetic, healing corneal epithelial cells: hyperglycemia-suppressed TGFβ3 expression contributes to the delay of epithelial wound healing in diabetic corneas.

Authors:  Ilham Bettahi; Haijing Sun; Nan Gao; Feng Wang; Xiaofan Mi; Weiping Chen; Zuguo Liu; Fu-Shin X Yu
Journal:  Diabetes       Date:  2013-12-04       Impact factor: 9.461

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.